Abstract
Novel therapeutics in oncology stem from a rational design of drugs targeting selective pathways that stimulate and maintain tumor cell growth. Many of these agents are cytostatic in action and also have a limited toxicity profile. However, some can be cytotoxic if they successfully modulate molecular pathways of apoptosis, such as bcl-2. This article discusses points to consider in the design of one class of cytostatic agents, antisense therapy. Our purpose is to stimulate designs that answer the question specifically with regard to proof-of-concept, and the concepts proposed should be viewed as ideas in development rather than firm recommendations.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 543-547 |
| Number of pages | 5 |
| Journal | Antisense and Nucleic Acid Drug Development |
| Volume | 9 |
| Issue number | 6 |
| State | Published - 1999 |
Fingerprint
ASJC Scopus subject areas
- Genetics
- Pharmacology
Cite this
Antisense therapeutics in oncology : Points to consider in their clinical evaluation. / Mani, Sridhar; Gu, Yun; Wadler, Scott; Fingert, Howard.
In: Antisense and Nucleic Acid Drug Development, Vol. 9, No. 6, 1999, p. 543-547.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Antisense therapeutics in oncology
T2 - Points to consider in their clinical evaluation
AU - Mani, Sridhar
AU - Gu, Yun
AU - Wadler, Scott
AU - Fingert, Howard
PY - 1999
Y1 - 1999
N2 - Novel therapeutics in oncology stem from a rational design of drugs targeting selective pathways that stimulate and maintain tumor cell growth. Many of these agents are cytostatic in action and also have a limited toxicity profile. However, some can be cytotoxic if they successfully modulate molecular pathways of apoptosis, such as bcl-2. This article discusses points to consider in the design of one class of cytostatic agents, antisense therapy. Our purpose is to stimulate designs that answer the question specifically with regard to proof-of-concept, and the concepts proposed should be viewed as ideas in development rather than firm recommendations.
AB - Novel therapeutics in oncology stem from a rational design of drugs targeting selective pathways that stimulate and maintain tumor cell growth. Many of these agents are cytostatic in action and also have a limited toxicity profile. However, some can be cytotoxic if they successfully modulate molecular pathways of apoptosis, such as bcl-2. This article discusses points to consider in the design of one class of cytostatic agents, antisense therapy. Our purpose is to stimulate designs that answer the question specifically with regard to proof-of-concept, and the concepts proposed should be viewed as ideas in development rather than firm recommendations.
UR - http://www.scopus.com/inward/record.url?scp=0033427291&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033427291&partnerID=8YFLogxK
M3 - Article
C2 - 10645781
AN - SCOPUS:0033427291
VL - 9
SP - 543
EP - 547
JO - Nucleic Acid Therapeutics
JF - Nucleic Acid Therapeutics
SN - 2159-3337
IS - 6
ER -